Maestro MEA Platform Powers First Stem Cell Cardiac Safety Assay in FDA ISTAND Program

/in , , , /by

ATLANTA, GA — Axion BioSystems today announced that the FDA’s Center for Drug Evaluation and Research (CDER) has accepted the company’s letter of intent (LOI) into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Program for its Human iPSC-Cardiomyocyte MEA Assay for Prediction of Clinical Cardiovascular Repolarization Risk. The submission represents the first stem cell-derived, […]

Read more →

New Pricing for epMotion 5073 to Enhance Liquid Handling Automation Accessibility

/in , /by

Eppendorf, a leading life sciences company, is excited to announce a substantial new price point for its popular epMotion 5073 automated liquid handling system. This change reflects Eppendorf’s commitment to making liquid handling automation more attainable for all laboratories, supporting greater efficiency and consistency in everyday lab workflows without compromising on Eppendorf’s known superior quality […]

Read more →

Cytion and AsedaSciences Announce Partnership to support Early Safety Prediction with Target Driven Cell Model Selection

/in , , , /by

3RnD® platform connects targets, compounds and authenticated human cell models to reduce manual searching and enable earlier, more informed R&D decisions By combining Cytion’s authenticated cell models with 3RnD’s data and AI workflow, we enable earlier, more reproducible and more actionable safety insight” — Jonathan Steubing, CEO, Cytion HEIDELBERG, BADEN-WüRTTEMBERG, GERMANY — Cytion, a trusted provider of […]

Read more →

Watchmaker Genomics Licenses CRISPR-Cas9 Intellectual Property from Caribou Biosciences to Increase Throughput and Reduce Sequencing Cost per Sample

/in , , , , , /by

BOULDER, Colo. — Watchmaker Genomics, an innovator in high-performance solutions for next-generation sequencing (NGS), today announced a non-exclusive license with Caribou Biosciences, Inc., a leading clinical-stage CRISPR genome-editing biopharmaceutical company, for certain foundational CRISPR-Cas9 intellectual property for use in NGS library preparation. While CRISPR-Cas9 technologies are most commonly associated with their unique ability to find […]

Read more →

Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage

/in , , , /by

Delivers up to 2× higher sensitivity than stainless steel microflow columns, lowering detection and quantitation limits across high-throughput bioseparations, DMPK, and ‘omics applications.1  Uses up to 75% less sample than 2.1 mm I.D. columns, conserving precious materials such as cell and gene therapy and personalized medicine candidates while delivering deeper insights. 2  Reduces solvent consumption by up to […]

Read more →

Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement

/in , , , , /by

B-Body® platform complements Twist’s antibody discovery offering enabling rapid, efficient and precise expression and discovery of complex bispecific antibody therapeutics Platform to power high-throughput characterization of bispecific antibodies to fuel AI-enabled and traditional drug discovery SOUTH SAN FRANCISCO, Calif. — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that it has […]

Read more →

Highly Efficient Skeletal Muscle Differentiation Kits

/in , , , /by

Amsbio has introduced an expanded range of Skeletal Muscle Differentiation Kits designed to reproducibly convert pluripotent or embryonic stem cells into myoblasts with high regenerative potential. Using a simple 3-step process of media changes and cell passaging – these advanced kits can typically achieve 70% MF20-positive myotubes. The highly efficient protocol employed by the kit does not require genetic intervention or cell sorting, […]

Read more →

BioLife solutions signs multi-year supply agreement with Qkine Limited to expand its product portfolio into the rapidly growing cytokines market

/in , , , /by

BOTHELL, Wash. —BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain ctokine and growth factor products manufactured by Qkine for use in cell and gene […]

Read more →

Apertura Gene Therapy Launches Open Aperture, a Material Transfer Agreement Program to Facilitate Non-Commercial Access to TfR1 CapX for Academic Researchers

/in , , , /by

— Open Aperture provides no-cost access to TfR1 CapX, a leading central nervous system-targeting AAV capsid — NEW YORK, NY – Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced the launch of Open Aperture, a material transfer agreement program that provides qualified academic researchers with access to […]

Read more →

New England Biolabs® launches Monarch® Mag Cell-free DNA (cfDNA) Extraction Kit to enable scalable, reproducible cfDNA isolation from biofluids

/in , , , , , /by

The automation-compatible, bead-based method optimizes cfDNA recovery from plasma, serum, urine and cerebrospinal fluid IPSWICH, Mass. — New England Biolabs (NEB®) announces the release of the Monarch Mag Cell-free DNA (cfDNA) Extraction Kit, which enables consistent, scalable extraction of low-abundance, circulating cell-free DNA (cfDNA) for downstream applications including biomarker discovery and diagnostics development. The magnetic, bead-based workflow is […]

Read more →